April 17th 2025
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results
September 4th 2024Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.
Dr. Bukavina on the need to improve female representation in bladder cancer clinical trials
September 2nd 2024“So, while the natural epidemiological prevalence of disease is only 20% to 30%, we really should aim for studies where we can oversample the females to make sure that that medication truly is doing what it's doing in both males and females,” says Laura Bukavina, MD, MPH, MS.
Armine K. Smith, MD, recaps BCAN session on oligometastatic bladder cancer
August 29th 2024"We have now realized that in some patients with a low number of metastatic sites, providing systemic treatment and providing some site-targeted treatment will provide lasting benefit or at least a temporary benefit that will help ameliorate the need for the systemic treatments or very intense systemic treatments," says Armine K. Smith, MD.
Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management
August 27th 2024Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.
Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs
August 22nd 2024“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.
Dr. Bjurlin on “super easy” way to implement smoking cessation in patients with bladder cancer
July 25th 2024"There are many opportunities to support our patients with bladder cancer who smoke from their clinic appointments from their intravesical therapy visits to their surveillance cystoscopies," says Marc Bjurlin, DO, MSc, FACOS.